

LACHMAN CONSULTANT SERVICES, INC.
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590
(516) 222-6222 • FAX (516) 683-1887

August 2, 2013

OVERNIGHT COURIER 8/2/13

Division of Dockets Management
Food and Drug Administration (HFA-305)
Department of Health and Human Services
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Citizen Petition

Dear Sir or Madam:

The undersigned submits this petition, in quadruplicate, pursuant to Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act, and in accordance with 21 CFR 10.30 on behalf of a client requesting the Commissioner of the Food and Drug Administration to declare that the drug product, Carisoprodol Tablets, 300 mg, is suitable for consideration in an abbreviated new drug application (ANDA).

A. Action Requested

The petitioner requests that the Commissioner of the Food and Drug Administration declare that the drug product, Carisoprodol Tablets, 300 mg, is suitable for submission in an ANDA. The reference listed drug product (RLD), upon which this petition is based, is Soma[®] (Carisoprodol) Tablets USP, 250 mg, NDA 011792 held by Meda Pharmaceuticals. This approved NDA also provides for Soma[®] Tablets in a 350 mg dosage strength. The petitioner seeks a change in strength (from 250 mg to 300 mg) from that of the listed drug product.

B. Statement of Grounds

The Federal Food, Drug and Cosmetic Act provides for the submission of an Abbreviated New Drug Application for a drug product that differs in dosage strength from that of the listed drug provided the FDA has approved a petition that proposed filing such an application.

The reference listed drug, Soma[®] Tablets, 250 mg, held by Meda Pharmaceuticals, is a tablet product containing 250 mg of Carisoprodol. See copy of the relevant page from the current Electronic Edition of the Approved Drug Product with Therapeutic Equivalence Evaluations (Attachment 1). The proposed drug product also represents a tablet dosage form, but contains 300 mg of Carisoprodol. The petition is thus seeking a change in strength (from 250 mg to 300 mg) from that of the RLD. Please note that the proposed change in strength represents a dosage strength that is clearly contemplated in the approved labeling for the RLD.

The current dosing instructions in the approved labeling of the RLD are as follows:

"The recommended dose of SOMA is 250 mg to 350 mg three times a day and at bedtime.
The recommended maximum duration of SOMA use is up to two or three weeks."

Thus, the additional strength of 300 mg would provide the healthcare practitioner with greater flexibility in dosing patients within the currently approved dosing range.

There are no proposed changes in labeling with the exception of the obvious change in strength sought in this petition and any information specifically related to the manufacturer or distributor. The uses,

2592 13 AUG-5 AM 1:12

indications, warnings and directions for use will remain the same as that of the RLD. Draft labeling for the proposed product is included in Attachment 2, and the approved labeling for the RLD is provided in Attachment 3.

Therefore, the petitioner's request for the Commissioner to find that a change in strength from 250 mg to 300 mg, for Carisoprodol Tablets should raise no questions of safety or effectiveness, and the Agency should approve the petition.

Inapplicability of the Pediatric Research Equity Act ("PREA"). PREA, which is codified at FDC Act § 505B, does not apply to a new strength, such as the one proposed in this Petition. (See FDC Act § 505B(a)(1)(A).) As such, PREA should not serve as an impediment to the Agency's granting of this Petition.

C. Environmental Impact

The petitioner claims a categorical exclusion under 21 CFR 25.31.


D. Economic Impact

The petitioner does not believe that this is applicable in this case, but will agree to provide such an analysis if requested by the Agency.

E. Certification

The undersigned certifies, that to the best knowledge and belief of the undersigned, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petitioner, which are unfavorable to the petition.

Respectfully submitted,


Christine Miller, Pharm.D
Associate Director

CCM/pk

- Attachments:
1. Approved Drug Product with Therapeutic Equivalence Evaluations, accessed July 18, 2013
 2. Draft Package Insert Labeling Proposed for Carisoprodol Tablets, 300 mg
 3. Labeling for the RLD, Soma[®] Tablets (Meda Pharmaceuticals)

cc: Martin Shimer (OGD)

Soma[®] is a registered trademark of Meda Pharmaceuticals.

Suitability Petition Carisoprodol

From: (516) 683-1881
 Westbury Office
 LACHMAN CONSULTANT SERVICES
 1600 STEWART AVE
 SUITE 604
 WESTBURY, NY 11590

Origin ID: RMEA



J13111302120326

Ship Date: 02AUG13
 ActWgt: 1.0 LB
 CAD: 105332656/INET3370

Delivery Address Bar Code




SHIP TO: (301) 827-6860

BILL SENDER

Division of Dockets Management
 FDA, DHHS, HFA-305
 5630 FISHERS LN RM 1061

ROCKVILLE, MD 20852

Ref # Citizen Petition
 Invoice #
 PO #
 Dept #




TRK# 7963 8371 7564

0201

MON - 05 AUG 3:00P
 STANDARD OVERNIGHT

DSR
 20852
 MD-US
 IAD

SA NSFA



518G1/AA04/93AB

After printing this label:

1. Use the 'Print' button on this page to print your label to your laser or inkjet printer.
2. Fold the printed page along the horizontal line.
3. Place label in shipping pouch and affix it to your shipment so that the barcode portion of the label can be read and scanned.

Warning: Use only the printed original label for shipping. Using a photocopy of this label for shipping purposes is fraudulent and could result in additional billing charges, along with the cancellation of your FedEx account number.

Use of this system constitutes your agreement to the service conditions in the current FedEx Service Guide, available on fedex.com. FedEx will not be responsible for any claim in excess of \$100 per package, whether the result of loss, damage, delay, non-delivery, misdelivery, or misinformation, unless you declare a higher value, pay an additional charge, document your actual loss and file a timely claim. Limitations found in the current FedEx Service Guide apply. Your right to recover from FedEx for any loss, including intrinsic value of the package, loss of sales, income interest, profit, attorney's fees, costs, and other forms of damage whether direct, incidental, consequential, or special is limited to the greater of \$100 or the authorized declared value. Recovery cannot exceed actual documented loss. Maximum for items of extraordinary value is \$1,000, e.g. jewelry, precious metals, negotiable instruments and other items listed in our Service Guide. Written claims must be filed within strict time limits, see current FedEx Service Guide.